The study plans to evaluate the impact of a personalized approach to breast cancer screening over an annual mammogram.
Laura Esserman, professor in the Department of Surgery and Radiology at the UCSF Helen Diller Comprehensive Cancer Center has always been an out-of-the-box thinker. Now, as she leads the Athena Breast Health Network, they are ready to launch the WISDOM (Women Informed to Screen Depending on Measures of Risk) study, which will evaluate the impact of a personalized approach to breast cancer screening over an annual mammogram.
As October, the Breast Cancer Awareness Month, rolls in Dr Esserman lists some important information about breast cancer to improve women's understanding of the disease:
"The essence of precision medicine is being able to tailor treatment to biology, patient preference and clinical performance," according to Esserman.
Read more here.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More